The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced L-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia

Dopamine (DA)-replacement therapy utilizing L-DOPA is the gold standard symptomatic treatment for Parkinson’s disease (PD). A critical complication of this therapy is the development of L-DOPA-induced dyskinesia (LID). The endogenous opioid peptides, including enkephalins and dynorphin, are co-trans...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuropharmacology
Autores principales: Flores, Andrew J., Bartlett, Mitchell J., Root, Brandon K., Parent, Kate L., Heien, Michael L., Porreca, Frank, Polt, Robin, Sherman, Scott J., Falk, Torsten
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6309213/
https://ncbi.nlm.nih.gov/pubmed/30201210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2018.09.005
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares